Successful treatment of patients with systemic lupus erythematosus complicated with autoimmune thyroid disease using double-filtration plasmapheresis: A retrospective study

Journal of Clinical Apheresis

Volumn 26, Issue 4, 2011, Pages 174-180

  Liu, Lin Lin ^a   Li, Xiao Li ^a   Wang, Li Ning ^a   Yao, Li ^a   Fan, Qiu Ling ^a   Li, Zi Long ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

autoimmune thyroid disease; double filtration plasmapheresis; systemic lupus erythematosus

Indexed keywords

THYROID ANTIBODY; THYROID HORMONE;

AUTOIMMUNE DISEASE; CLINICAL ARTICLE; DISEASE ACTIVITY; DOUBLE FILTRATION PLASMAPHERESIS; EVALUATION AND FOLLOW UP; FATALITY; FEMALE; GENERAL CONDITION IMPROVEMENT; GLOMERULUS FILTRATION RATE; HEALTH CARE FACILITY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MEDICAL RECORD REVIEW; PLASMAPHERESIS; PNEUMONIA; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE; TREATMENT RESPONSE;

ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PLASMAPHERESIS; RETROSPECTIVE STUDIES; THYROID DISEASES; TREATMENT OUTCOME;

EID: 80051494790     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20287     Document Type: Review

References (21)

1. Mosca M, Bombardieri S,. Disease-specific quality indicators, guide-lines, and outcome measures in systemic lupus erythematosus. Clin Exp Rheumatol 2007; 25: 107-113.
2. Griffiths B, Mosca M, Gordon C,. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005; 19: 685-708. (Pubitemid 41258578)
3. Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, Manji N, Allahabadia A, Armitage M, Chatterjee KV, Lazarus JH, Pearce SH, Vaidya B, Gough SC, Franklyn JA,. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010; 123: 183.e1-9.
4. Chan AT, Al-Saffar Z, Bucknall RC,. Thyroid disease in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 353-354. (Pubitemid 32266365)
5. Antonelli A, Mosca M, Fallahi P, Neri R, Ferrari SM, D'Ascanio A, Ghiri E, Carli L, Miccoli P, Bombardieri S,. Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab 2010; 95: 314-318.
6. Wei N, Klippel JH, Huston DP, Hall RP, Lawley TJ, Balow JE, Steinberg AD, Decker JL,. A randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983; 1: 17-22. (Pubitemid 13211281)
7. Jones JV, Robinson MF, Parciany RK, Layfer LF, McLeod B,. Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA. Arthritis Rheum 1981; 24: 1113-1120. (Pubitemid 11057337)
8. Koo AP,. Therapeutic apheresis in autoimmune and rheumatic diseases. J Clin Apher 2000; 15: 18-27. (Pubitemid 30176812)
9. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH,. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25: 83-177.
10. Hochberg MC,. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
11. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M,. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938. (Pubitemid 29514229)
12. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.
13. Stamatiadis DN, Helioti H, Mansour M, Pappas M, Bokos JG, Stathakis CP,. Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe and efficient. Clin Nephrol 2004; 62: 29-34. (Pubitemid 38979106)
14. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D,. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-1285.
15. Jones JV, Cumming RH, Bucknall RC, Asplin CM,. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976; 1: 709-711.
16. 131I) in hyperthyroid patients. Endokrynol Pol 2010; 61: 56-61.
17. Vanderpump MP,. Thyroid gland: use of glucocorticoids in amiodarone-induced thyrotoxicosis. Nat Rev Endocrinol 2009; 5: 650-651.
18. Mao XM, Li HQ, Li Q, Li DM, Xie XJ, Yin GP, Zhang P, Xu XH, Wu JD, Chen SW, Wang SK,. Prevention of relapse of Graves' disease by treatment with an intrathyroid injection of Dexamethasone. J Clin Endocrinol Metab 2009; 94: 4984-4991.
19. Madore F,. Plasmapheresis technical aspects and indications. Crit Care Clin 2002; 18: 375-392. (Pubitemid 34556518)
20. Hanafusa N, Kondo Y, Suzuki M, Nakao A, Noiri E, Fujita T,. Double filtration plasmapheresis can decrease factor XIII Activity. Ther Apher Dial 2007; 11: 165-170. (Pubitemid 46716162)
21. Seishima M, Shibuya Y, Kato G, Aoki T,. Decreased factor XIII activity in a patient with subcutaneous bleeding after double filtration plasmapheresis. Ther Apher Dial 2009; 13: 229-231.